These results contrast those for dupilumab in COVID-19, which demonstrated a probable clinical benefit of dupilumab and an associated reduction in type II inflammatory cytokines (e.g., eotaxin-3 and YKL-40) compared to placebo (8). This evidence concerns the gene CCL26 and COVID-19.